DOCSLIB.ORG

Bone Matrix Non-Collagenous Proteins in Tissue Engineering: Creating New Bone by Mimicking the Extracellular Matrix

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bone Matrix Non-Collagenous Proteins in Tissue Engineering: Creating New Bone by Mimicking the Extracellular Matrix polymers Review Bone Matrix Non-Collagenous Proteins in Tissue Engineering: Creating New Bone by Mimicking the Extracellular Matrix Marta S. Carvalho 1,2,3,* , Joaquim M. S. Cabral 2,3 , Cláudia L. da Silva 2,3 and Deepak Vashishth 1,* 1 Center for Biotechnology and Interdisciplinary Studies, Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA 2 Department of Bioengineering and iBB—Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal; [email protected] (J.M.S.C.); [email protected] (C.L.d.S.) 3 Associate Laboratory i4HB—Institute for Health and Bioeconomy, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal * Correspondence: [email protected] (M.S.C.); [email protected] (D.V.) Abstract: Engineering biomaterials that mimic the extracellular matrix (ECM) of bone is of significant importance since most of the outstanding properties of the bone are due to matrix constitution. Bone ECM is composed of a mineral part comprising hydroxyapatite and of an organic part of primarily collagen with the rest consisting on non-collagenous proteins. Collagen has already been described as critical for bone tissue regeneration; however, little is known about the potential effect of non-collagenous proteins on osteogenic differentiation, even though these proteins were identified some decades ago. Aiming to engineer new bone tissue, peptide-incorporated biomimetic materials have been developed, presenting improved biomaterial performance. These promising results led to ongoing research focused on incorporating non-collagenous proteins from bone matrix to Citation: Carvalho, M.S.; Cabral, enhance the properties of the scaffolds namely in what concerns cell migration, proliferation, and J.M.S.; da Silva, C.L.; Vashishth, D. differentiation, with the ultimate goal of designing novel strategies that mimic the native bone ECM Bone Matrix Non-Collagenous for bone tissue engineering applications. Overall, this review will provide an overview of the several Proteins in Tissue Engineering: Creating New Bone by Mimicking the non-collagenous proteins present in bone ECM, their functionality and their recent applications in Extracellular Matrix. Polymers 2021, the bone tissue (including dental) engineering field. 13, 1095. https://doi.org/10.3390/ polym13071095 Keywords: non-collagenous proteins; extracellular matrix; bone tissue engineering; biomimetic scaf- folds Academic Editor: Alessandro Pistone Received: 28 February 2021 Accepted: 20 March 2021 1. Introduction Published: 30 March 2021 New promising solutions for bone tissue engineering have been developed over the last years following the dramatic increase of the number of bone-related medical conditions Publisher’s Note: MDPI stays neutral that require clinical interventions. In fact, each year, more than one million non-union with regard to jurisdictional claims in fractures are treated in the United States [1]. Moreover, 5–10% of the bone fractures that published maps and institutional affil- occur worldwide do not heal [1]. Besides bone fractures, bone tissue can also be damaged iations. by traumas, tumors, infections, or bone diseases. Furthermore, new strategies to engineer bone tissue are required as an alternative to the use of bone grafts, addressing the increasing worldwide incidence of bone disorders in an aging society severely impacted by obesity, lack of exercise, and with reducing healing capacity [2]. Even though bone tissue engi- Copyright: © 2021 by the authors. neering appears as a promising alternative, to date the gold-standard treatment for bone Licensee MDPI, Basel, Switzerland. regeneration still relies on bone grafts, autologous, allogenic, and xenogeneic grafts [1] This article is an open access article (Figure1). These approaches have some limitations and are not ideal for bone regenera- distributed under the terms and tion. Autografts have been applied since they can provide a matrix with osteogenic cells conditions of the Creative Commons and osteoinductive factors to support new bone growth, without having immunological Attribution (CC BY) license (https:// rejection and promote better osseointegration. Nonetheless, the availability of quality graft creativecommons.org/licenses/by/ material is limited and possible complications may occur, such as pain, infections, scarring, 4.0/). Polymers 2021, 13, 1095. https://doi.org/10.3390/polym13071095 https://www.mdpi.com/journal/polymers Polymers 2021, 13, 1095 2 of 33 and weakening of the donor bone. Moreover, there is a high morbidity associated with this procedure, since more than one surgery is needed [1,3]. Allografts, usually harvested from cadavers, have also some limitations, namely the higher risk of immunologic rejection and infection though it requires less procedures than autografts, minimizing the surgical time and accelerating the patient recovery [3]. As an alternative to allografts, xenografts consist of transplantation of bone tissue across species. The most common xenograft used in orthopedic surgery is bovine derived. Xenografts have some advantages compared to other grafts, such as being readily available due to the abundance of donor bone tissue and being less expensive than allografts [2,3]. In fact, commercially-available xenografts are approximately one-tenth the price of commercially-available allografts. Also, because of Polymers 2021, 13, x FOR PEER REVIEW 28 of 34 the extensive sterilization processes, their shelf life is generally long. However, xenografts present several challenges such as the risk of disease transmission and a higher risk of im- mune response of the host tissue compared to allografts [3]. Moreover, xenografts require intensive sterile processing, which can decrease their osteoinductive properties. FigureFigure 1. Comparison 1. Comparison between between autografts, autografts, allografts, allografts, and and xenografts: xenografts: Advantages Advantages and disadvantages. and disadvantages. Bone tissue engineering has the potential for solving these problems by combining different elements such as cells, molecules, and scaffolds. The standard tissue engineering approach uses a combination of growth factors, scaffolds and osteogenic cells (triangular Polymers 2021, 13, 1095 3 of 33 Polymers 2021, 13, x FOR PEER REVIEW 29 of 34 Bone tissue engineering has the potential for solving these problems by combining concept).different elementsHowever, such Giannoudis as cells, molecules,and colleagues and scaffolds.developed The and standard discussed tissue a new engineering concept, theapproach diamond uses concept, a combination in which of a growth fourth factors,element, scaffolds vascularization, and osteogenic should cellsbe also (triangular consid- eredconcept). as a contributor However, Giannoudisto bone healing. and colleaguesThus, the diamond developed concept and discussed in bone tissue a new engineer- concept, ingthe diamondcombines concept, four basic in whichelements a fourth [4]: (i) element, A biomaterial vascularization, with osteogenic should be ability also considered for bone formationas a contributor that acts to as bone a scaffold healing. for Thus, the other the diamond elements; concept (ii) osteogenic in bone cells tissue capable engineering to cre- atingcombines or inducing four basic new elements bone formation [4]: (i) A at biomaterial the defect site; with (iii) osteogenic osteoinductive ability formolecules bone forma- that triggertion that cells acts and as arecruit scaffold resident for the cells other to elements; form new (ii) functional osteogenic bone cells tissue; capable and to (iv) creating vascu- or larizationinducing newto support bone formation the viability at theof the defect defect site; site (iii) thus osteoinductive allowing the molecules diffusion that of oxygen trigger andcells nutrients and recruit to the resident defect cells region to form (Figure new 2). functional bone tissue; and (iv) vascularization to support the viability of the defect site thus allowing the diffusion of oxygen and nutrients to the defect region (Figure2). A B Biomolecules immobilized to enhance cell functions Figure 2. Bone tissue engineering strategies. (A) The bone tissue engineering paradigm highlights (1) Biomimetic scaffold, Figure(2) osteogenic 2. Bone cells,tissue (3) engineering osteoinductive strategies. molecules, (A) The and bone (4) tissue vascularization. engineering ( Bparadigm) Schematic highlights representation (1) Biomimetic of biomolecules scaffold, (2)immobilized osteogenic into cells, a porous (3) osteoinductive scaffold (left) molecules, and a functionalized and (4) vascularization. hydrogel with bioactive (B) Schematic peptides representation and cells incorporated of biomolecules (right). immobilized into a porous scaffold (left) and a functionalized hydrogel with bioactive peptides and cells incorporated (right). Several scaffolds have been developed for bone tissue engineering, including natural biomaterials (such as collagen, gelatin, and chitosan), ceramic implants (such as hydrox- yapatite),Several polymeric scaffolds synthetichave been materials developed (such for bone as polylactic tissue engineering, acid (PLA) including and polyglycolic natural biomaterialsacid (PGA)) (such and composite as collagen, scaffolds gelatin, [and5]. Even chitosan), though ceramic materials implants science (such technology as hydroxy- has apatite),resulted polymeric in clear
Load more

Recommended publications
  • Functions of Osteocalcin in Bone, Pancreas, Testis, and Muscle
    International Journal of Molecular Sciences Review Functions of Osteocalcin in Bone, Pancreas, Testis, and Muscle Toshihisa Komori Basic and Translational Research Center for Hard Tissue Disease, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan; [email protected]; Tel.: +81-95-819-7637; Fax: +81-95-819-7638 Received: 17 September 2020; Accepted: 10 October 2020; Published: 12 October 2020 Abstract: Osteocalcin (Ocn), which is specifically produced by osteoblasts, and is the most abundant non-collagenous protein in bone, was demonstrated to inhibit bone formation and function as a hormone, which regulates glucose metabolism in the pancreas, testosterone synthesis in the testis, / / and muscle mass, based on the phenotype of Ocn− − mice by Karsenty’s group. Recently, Ocn− − mice were newly generated by two groups independently. Bone strength is determined by bone / quantity and quality. The new Ocn− − mice revealed that Ocn is not involved in the regulation of bone formation and bone quantity, but that Ocn regulates bone quality by aligning biological apatite (BAp) parallel to the collagen fibrils. Moreover, glucose metabolism, testosterone synthesis and / spermatogenesis, and muscle mass were normal in the new Ocn− − mice. Thus, the function of Ocn is the adjustment of growth orientation of BAp parallel to the collagen fibrils, which is important for bone strength to the loading direction of the long bone. However, Ocn does not play a role as a hormone in the pancreas, testis, and muscle. Clinically, serum Ocn is a marker for bone formation, and exercise increases bone formation and improves glucose metabolism, making a connection between Ocn and glucose metabolism.
    [Show full text]
  • Undenatured Type II Collagen Mechanism of Action
    Undenatured Type II Collagen Mechanism of Action Page Executive Summary .................... 2 Animal Research ......................... 3 In Vitro Research ........................ 4 For Professional Use Only UC-II® Undenatured Type II Collagen (Mechanism of Action) Executive Summary UC-II® undenatured type II collagen is a patented form of collagen with undenatured (native) type II collagen for joint health support. A small amount (40 mg/day) is believed to work by inducing a process known as oral tolerance that ultimately engages the immune system in the repair of its own joint cartilage. Oral tolerance is an immune process that allows the body to distinguish between innocuous compounds such as dietary proteins and intestinal bacteria and potentially harmful foreign invaders. In the digestive tract, oral tolerance occurs in the gut-associated lymphoid tissue (GALT), considered to be the body’s most abundant lymphoid tissue. The GALT is primarily composed of mesenteric lymph nodes and patches of lymphoid tissue surrounding the small intestine called Peyer’s patches. It is in the Peyer’s patches, which contain an organized collection of immune cells, where most of the immune responses in the digestive tract are generated. Through a cascade of immunological events, Peyer’s patches take in and screen compounds from the gut lumen and, depending on the compound, turn the body’s immune response on or off (Weiner et al1). Researchers believe UC-II® undenatured type II collagen induces a form of oral tolerance that results from exposure to a compound in small amounts. More specifically, UC-II® undenatured type II collagen is believed to be transported across the gut epithelial cells to the underlying immune cells in the Peyer’s patches where it activates naive T cells to become T regulatory (Treg) cells that specifically target type II collagen.
    [Show full text]
  • Global Analysis Reveals the Complexity of the Human Glomerular Extracellular Matrix
    Global analysis reveals the complexity of the human glomerular extracellular matrix Rachel Lennon,1,2 Adam Byron,1,* Jonathan D. Humphries,1 Michael J. Randles,1,2 Alex Carisey,1 Stephanie Murphy,1,2 David Knight,3 Paul E. Brenchley,2 Roy Zent,4,5 and Martin J. Humphries.1 1Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, UK; 2Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK; 3Biological Mass Spectrometry Core Facility, Faculty of Life Sciences, University of Manchester, Manchester, UK; 4Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; and 5Veterans Affairs Hospital, Nashville, TN, USA. *Present address: Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. Running title: Proteome of the glomerular matrix Word count: Abstract: 208, main text 2765 Corresponding author: Dr Rachel Lennon, Wellcome Trust Centre for Cell-Matrix Research, Michael Smith Building, University of Manchester, Manchester M13 9PT, UK. Phone: 0044 (0) 161 2755498. Fax: 0044 (0) 161 2755082. Email: [email protected] Abstract The glomerulus contains unique cellular and extracellular matrix (ECM) components, which are required for intact barrier function. Studies of the cellular components have helped to build understanding of glomerular disease; however, the full composition and regulation of glomerular ECM remains poorly understood. Here, we employed mass spectrometry–based proteomics of enriched ECM extracts for a global analysis of human glomerular ECM in vivo and identified a tissue-specific proteome of 144 structural and regulatory ECM proteins. This catalogue includes all previously identified glomerular components, plus many new and abundant components.
    [Show full text]
  • Native Type II Collagen for Joint Health: Small Dose, Big Benefits
    Print this Document! Native Type II Collagen for Joint Health: Small Dose, Big Benefits By Cai Berg Collagens are the most abundant family of proteins in the extracellular matrix of connective tissues. They perform a variety of biological functions, the best known of which is providing the structural framework for tissues throughout the body. Based on their supramolecular organization, 26 different types of collagen have been identified, each with its own role and position in the body. Type II collagen is the main structural protein in the cartilage. It provides tensile strength and toughness to the tissue. Joint disorders involving inflammation and cartilage erosion, such as arthritis, are often characterized by an autoimmune component in which the immune system acts against the body's own type II collagen. Studies have shown that supplementing native (undenatured) type II collagen can help modulate the destructive immune response against endogenous type II collagen to support joint health and comfort.1 Not All Collagens Are Equal Collagen and collagen derivatives have been investigated and employed for joint nourishment for decades. Collagen products are defined by their degree of hydrolyzation and their molecular weight as either undenatured (native) collagen, collagen hydrolysate (hydrolyzed collagen) or gelatin. Undenatured (native) collagen has the highest molecular weight (300 kDA), while hydrozyled collagen ranges from 2 to 9 kDa. Unlike gelatin and hydrolyzed collagen supplements, which are intended to be absorbed to augment the collagen needs of various cells and tissues, native type II collagen supplements work through a mechanism known as oral tolerization. This immune-mediated process involves ingestion of an autoantigen (in this case, type II collagen) in order to suppress the immune response against endogenous tissue.
    [Show full text]
  • Large-Scale Serum Protein Biomarker Discovery in Duchenne Muscular Dystrophy
    Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy Yetrib Hathouta, Edward Brodyb, Paula R. Clemensc,d, Linda Cripee, Robert Kirk DeLisleb, Pat Furlongf, Heather Gordish- Dressmana, Lauren Hachea, Erik Henricsong, Eric P. Hoffmana, Yvonne Monique Kobayashih, Angela Lortsi, Jean K. Mahj, Craig McDonaldg, Bob Mehlerb, Sally Nelsonk, Malti Nikradb, Britta Singerb, Fintan Steeleb, David Sterlingb, H. Lee Sweeneyl, Steve Williamsb, and Larry Goldb,1 aResearch Center for Genetic Medicine, Children’s National Medical Center, Washington, DC 20012; bSomaLogic, Inc., Boulder, CO 80301; cNeurology Service, Department of Veteran Affairs Medical Center, Pittsburgh, PA 15240; dUniversity of Pittsburgh, Pittsburgh, PA 15213; eThe Heart Center, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH 15213; fParent Project Muscular Dystrophy, Hackensack, NJ 07601; gDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Davis, CA 95618; hDepartment of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN 46202; iThe Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229; jDepartment of Pediatrics, University of Calgary, Alberta Children’s Hospital, Calgary, AB, Canada T3B 6A8; kDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO 80045; and lDepartment of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL 32610 Contributed
    [Show full text]
  • Supp Table 1.Pdf
    Upregulated genes in Hdac8 null cranial neural crest cells fold change Gene Symbol Gene Title 134.39 Stmn4 stathmin-like 4 46.05 Lhx1 LIM homeobox protein 1 31.45 Lect2 leukocyte cell-derived chemotaxin 2 31.09 Zfp108 zinc finger protein 108 27.74 0710007G10Rik RIKEN cDNA 0710007G10 gene 26.31 1700019O17Rik RIKEN cDNA 1700019O17 gene 25.72 Cyb561 Cytochrome b-561 25.35 Tsc22d1 TSC22 domain family, member 1 25.27 4921513I08Rik RIKEN cDNA 4921513I08 gene 24.58 Ofa oncofetal antigen 24.47 B230112I24Rik RIKEN cDNA B230112I24 gene 23.86 Uty ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 22.84 D8Ertd268e DNA segment, Chr 8, ERATO Doi 268, expressed 19.78 Dag1 Dystroglycan 1 19.74 Pkn1 protein kinase N1 18.64 Cts8 cathepsin 8 18.23 1500012D20Rik RIKEN cDNA 1500012D20 gene 18.09 Slc43a2 solute carrier family 43, member 2 17.17 Pcm1 Pericentriolar material 1 17.17 Prg2 proteoglycan 2, bone marrow 17.11 LOC671579 hypothetical protein LOC671579 17.11 Slco1a5 solute carrier organic anion transporter family, member 1a5 17.02 Fbxl7 F-box and leucine-rich repeat protein 7 17.02 Kcns2 K+ voltage-gated channel, subfamily S, 2 16.93 AW493845 Expressed sequence AW493845 16.12 1600014K23Rik RIKEN cDNA 1600014K23 gene 15.71 Cst8 cystatin 8 (cystatin-related epididymal spermatogenic) 15.68 4922502D21Rik RIKEN cDNA 4922502D21 gene 15.32 2810011L19Rik RIKEN cDNA 2810011L19 gene 15.08 Btbd9 BTB (POZ) domain containing 9 14.77 Hoxa11os homeo box A11, opposite strand transcript 14.74 Obp1a odorant binding protein Ia 14.72 ORF28 open reading
    [Show full text]
  • TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 39, No. 3, 343-352, June 2007 TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice 1,2,3 2 Eun-Yi Moon and Sook-Kyung Ryu the percentage of non-lymphoid cells and no changes were detected in lymphoid cell population. 1 Department of Bioscience and Biotechnology Hypodiploid cell formation in BALF was decreased Sejong University by OVA-challenge but it was recovered by TACI:Fc Seoul 143-747, Korea treatment. Collectively, data suggest that asthmatic 2 Laboratory of Human Genomics symptom could be alleviated by scavenging BAFF Korea Research Institute of Bioscience and Biotechnology (KRIBB) and then BAFF could be a novel target for the Daejeon 305-806, Korea develpoment of anti-asthmatic agents. 3 Corresponding author: Tel, 82-2-3408-3768; Fax, 82-2-466-8768; E-mail, [email protected] Keywords: asthma; B-cell activating factor; ovalbu- and [email protected] min; transmembrane activator and CAML interactor protein Accepted 28 March 2007 Introduction Abbreviations: BAFF, B cell activating factor belonging to TNF- family; BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; PAS, Mature B cell generation and maintenance are regu- periodic acid-Schiff; Prx, peroxiredoxin; TACI, transmembrane lated by B-cell activating factor (BAFF). BAFF is pro- activator and calcium modulator and cyclophilin ligand interactor duced by macrophages or dendritic cells upon stim- ulation with LPS or IFN- . BAFF belongs to the TNF family. Its biological role is mediated by the specific Abstract receptors, B-cell maturation antigen (BCMA), trans- membrane activator and calcium modulator and cy- Asthma was induced by the sensitization and chal- clophilin ligand interactor (TACI) and BAFF receptor, lenge with ovalbumin (OVA) in mice.
    [Show full text]
  • A Selective ER-Phagy Exerts Procollagen Quality Control Via a Calnexin-FAM134B Complex
    Article A selective ER-phagy exerts procollagen quality control via a Calnexin-FAM134B complex Alison Forrester1,†, Chiara De Leonibus1,†, Paolo Grumati2,†, Elisa Fasana3,†, Marilina Piemontese1, Leopoldo Staiano1, Ilaria Fregno3,4, Andrea Raimondi5, Alessandro Marazza3,6, Gemma Bruno1, Maria Iavazzo1, Daniela Intartaglia1, Marta Seczynska2, Eelco van Anken7, Ivan Conte1, Maria Antonietta De Matteis1,8, Ivan Dikic2,9,* , Maurizio Molinari3,10,** & Carmine Settembre1,11,*** Abstract The EMBO Journal (2019) 38:e99847 Autophagy is a cytosolic quality control process that recognizes substrates through receptor-mediated mechanisms. Procollagens, Introduction the most abundant gene products in Metazoa, are synthesized in the endoplasmic reticulum (ER), and a fraction that fails to attain Macroautophagy (hereafter referred to as autophagy) is a homeostatic the native structure is cleared by autophagy. However, how auto- catabolic process devoted to the sequestration of cytoplasmic material phagy selectively recognizes misfolded procollagens in the ER in double-membrane vesicles (autophagic vesicles, AVs) that eventu- lumen is still unknown. We performed siRNA interference, CRISPR- ally fuse with lysosomes where cargo is degraded (Mizushima, 2011). Cas9 or knockout-mediated gene deletion of candidate autophagy Autophagy is essential to maintain tissue homeostasis and counter- and ER proteins in collagen producing cells. We found that the ER- acts both the onset and progression of many disease conditions, such resident lectin chaperone Calnexin (CANX) and the ER-phagy as ageing, neurodegeneration and cancer (Levine et al, 2015). receptor FAM134B are required for autophagy-mediated quality Substrates can be selectively delivered to AVs through receptor- control of endogenous procollagens. Mechanistically, CANX acts as mediated processes. Autophagy receptors harbour a LC3 or GABARAP co-receptor that recognizes ER luminal misfolded procollagens and interaction motif (LIR or GIM, respectively) that facilitate binding of interacts with the ER-phagy receptor FAM134B.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Dietary Protein Restriction Rapidly Reduces Transforming Growth Factor
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 9765-9769, November 1991 Medical Sciences Dietary protein restriction rapidly reduces transforming growth factor p1 expression in experimental glomerulonephritis (extraceliular matrix/transforming growth factor 8/glomerulonephritis) SEIYA OKUDA*, TAKAMICHI NAKAMURA*, TATSUO YAMAMOTO*, ERKKI RUOSLAHTIt, AND WAYNE A. BORDER*t *Division of Nephrology, University of Utah School of Medicine, Salt Lake City, UT 84132; and tCancer Research Center, La Jolla Cancer Research Foundation, La Jolla, CA 92037 Communicated by Eugene Roberts, August 19, 1991 (receivedfor review April 29, 1991) ABSTRACT Dietary protein restriction has been shown to TGF-/31 on both cell types is to regulate the synthesis of two slow the rate of loss of kidney function in humans with chondroitin/dermatan sulfate proteoglycans, biglycan and progressive glomerulosclerosis due to glomerulonephritis or decorin, both of which can bind TGF-P1 (23). In an experi- diabetes mellitus. A central feature of glomerulosclerosis is the mental model ofglomerulonephritis in the rat, we have found pathological accumulation of extracellular matrix within the a close association between elevated expression of the diseased glomeruli. Transforming growth factor j1 (TGF-.81) TGF-131 gene and the development of glomerulonephritis is known to have widespread regulatory effects on extracellular (10). Seven days after glomerular injury, at the time of matrix and has been implicated as a major cause of increased significant extracellular matrix accumulation, the glomeruli extracellular matrix synthesis and buildup of pathological showed a 5-fold increase in TGF-f31 mRNA and a nearly matrix within glomeruli in experimental glomerulonephritis. 50-fold increase in production ofbiglycan and decorin.
    [Show full text]
  • Aggrecan (A1960)
    Aggrecan from bovine articular cartilage Catalog Number A1960 Storage Temperature –20 °C Product Description References Aggrecan is the major structural proteoglycan found in 1. Hardingham, T.E., and Muir, H., Biochim. Biophys. the extracellular matrix of cartilage. It has a molecular Acta, 279, 401-405 (1972). mass >2,500 kDa. The core protein (210–250 kDa) has 2. Hedlund, H., et al., Association of the aggrecan 100–150 glycosaminoglycan (GAG) chains attached to keratan sulfate-rich region with collagen in bovine it. The majority of the GAG chains are chondroitin/ articular cartilage. J. Biol. Chem., 274, 5777-5781 dermatan sulfate with the remainder being keratan (1999). sulfate. This structural molecule produces a rigid, 3. Cao, L., and Yang, B.B., Chondrocyte apoptosis reversibly deformable gel that resists compression. It induced by aggrecan G1 domain as a result of combines with hyaluronic acid to form very large decreased cell adhesion. Exp. Cell Res., 246, 527- macromolecular complexes. Addition of small amounts 537 (1999). (0.1–2% w/w) of hyaluronic acid to a solution of 4. Bolton, M.C., et al., Age-related changes in the aggrecan (2 mg/ml) results in the formation of a synthesis of link protein and aggrecan in human complex with an increased hydrodynamic volume and articular cartilage: implications for aggregate in a significant increase (30–40%) in the relative stability. Biochem. J., 337, 77-82 (1999). viscosity of the solution. 5. Arner, E.C., et al., Generation and Characterization of Aggrecanase. A soluble, cartilage-derived Aggrecan is a critical component for cartilage structure aggrecan-degrading activity.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Figure S1. Bioinformatics evaluation of dystrophin isoform Dp427 and its central position in the molecular pathogenesis of X-linked muscular dystrophy. In order to generate a protein interaction map with known and predicted protein associations that include direct physical and indirect functional protein linkages, the bioinformatics STRING database [1,2] was used to analyse mass spectrometrically-identified proteins with a changed abundance in mdx-4cv skeletal muscles (Tables 1 and 2). S2 Figure S2. Focus of the bioinformatics evaluation of dystrophin isoform Dp427 and its central position in the molecular pathogenesis of X-linked muscular dystrophy. Shown is the middle part of the interaction map of altered muscle-associated proteins from mdx-4cv hind limb muscles, focusing on the central position of the dystrophin protein Dp427 (marked in yellow). In order to generate a protein interaction map with known and predicted protein associations that include direct physical and indirect functional protein linkages, the bioinformatics STRING database [1,2] was used to analyse mass spectrometrically-identified proteins with a changed abundance in mdx-4cv skeletal muscles (Tables 1 and 2). S3 Table S1. List of identified proteins that exhibit a significantly altered concentration in crude mdx-4cv hind limb muscle preparations as revealed by label-free LC-MS/MS analysis. This table contains the statistical q-values of the proteins listed in Tables 1 and 2. Accession Peptide Max Fold Highest Mean Description q Value Number
    [Show full text]